Citius Oncology (CTOR) Cash from Operations (2023 - 2026)

Citius Oncology (CTOR) posted quarterly Cash from Operations of 3831618.0 for Q1 2026, up 47.9% quarter-over-quarter from 7354946.0 in Q4 2025.

Citius Oncology (CTOR) Cash from Operations (2023 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Cash from Operations for 4 consecutive years, with 3831618.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Cash from Operations changed N/A year-over-year to 3831618.0; the TTM figure through Mar 2026 stood at 11744360.0 (changed N/A YoY), while the FY2025 annual figure was 5492046.0, down 4446.59% from the prior year.
Cash from Operations grew to 3831618.0 in Q1 2026 per CTOR's latest filing, from 7354946.0 in the prior quarter.
Across five years, Cash from Operations topped out at 100256.0 in Q2 2023 and bottomed at 7354946.0 in Q4 2025.
Historically, Cash from Operations has averaged 1770848.86 across 4 years, with a median of 366106.0 in 2024.
On a YoY basis, Cash from Operations climbed as much as 13.56% in 2024 and fell as far as 265.17% in 2024.
Citius Oncology's Cash from Operations stood at 382527.0 in 2023, then grew by 4.29% to 366106.0 in 2024, then plunged by 1908.97% to 7354946.0 in 2025, then soared by 47.9% to 3831618.0 in 2026.
Business Quant data shows CTOR's Cash from Operations at 3831618.0 in Q1 2026, 7354946.0 in Q4 2025, and 366106.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Ops. (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	411.00 Mn
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	655.00 Mn
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	800.69 Mn
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	313.60 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	381.80 Mn
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	136.40 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	277.00 Mn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	-
10	Citius Oncology	81.12 Mn	81.12 Mn	1.00 Mn	-2.71 Mn

Download Data